Personalized vaccine for high-risk triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had stage II or III triple-negative breast cancer (ER/PR less than 10%, HER2-negative).
- You completed standard chemotherapy and surgery, but there was still a significant amount of tumor left (doctors call this 'residual disease').
- You are 18 years or older.
- You are generally healthy, with a performance status that allows for daily activities (ECOG 0 or 1).
- You have enough leftover tumor tissue from your surgery that can be used for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This trial tests a personalized cancer vaccine designed to train your immune system to fight triple negative breast cancer. It is for people who are already receiving or about to receive the standard KEYNOTE 522 treatment, and the vaccine is given after a few months of that treatment.
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.